Untitled

Ishida, Osamu; Maruyama, Kazuo; Tanahashi, Hiroyuki; Iwatsuru, Motoharu; Sasaki, Katsunori; Eriguchi, Masazumi; Yanagië, Hironobu

doi:10.1023/a:1010960900254

Cited by 246 publications

(53 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even within the nano-scale range, size variation strongly affects bioavailability and blood circulation time [8,9]. Following systemic administration, particles with diameters less than 10 nm are rapidly removed through extravasation and renal clearance [7]; particles with diameters ranging from 10 to 70 nm can penetrate even very small capillaries [10]; particles with diameters ranging from 70 to 200 nm demonstrate the most prolonged circulation times [8]; and particles with diameters greater than 200 nm are usually sequestered by the spleen and eventually removed by phagocytes [11].…”

Section: Introductionmentioning

confidence: 99%

Nanostructured materials for applications in drug delivery and tissue engineering

Goldberg

Langer

Jia

2007

Journal of Biomaterials Science, Polymer Edition

943

554

View full text Add to dashboard Cite

Research in the areas of drug delivery and tissue engineering has witnessed tremendous progress in recent years due to their unlimited potential to improve human health. Meanwhile, the development of nanotechnology provides opportunities to characterize, manipulate and organize matter systematically at the nanometer scale. Biomaterials with nano-scale organizations have been used as controlled release reservoirs for drug delivery and artificial matrices for tissue engineering. Drug-delivery systems can be synthesized with controlled composition, shape, size and morphology. Their surface properties can be manipulated to increase solubility, immunocompatibility and cellular uptake. The limitations of current drug delivery systems include suboptimal bioavailability, limited effective targeting and potential cytotoxicity. Promising and versatile nano-scale drug-delivery systems include nanoparticles, nanocapsules, nanotubes, nanogels and dendrimers. They can be used to deliver both small-molecule drugs and various classes of biomacromolecules, such as peptides, proteins, plasmid DNA and synthetic oligodeoxynucleotides. Whereas traditional tissue-engineering scaffolds were based on hydrolytically degradable macroporous materials, current approaches emphasize the control over cell behaviors and tissue formation by nano-scale topography that closely mimics the natural extracellular matrix (ECM). The understanding that the natural ECM is a multifunctional nanocomposite motivated researchers to develop nanofibrous scaffolds through electrospinning or self-assembly. Nanocomposites containing nanocrystals have been shown to elicit active bone growth. Drug delivery and tissue engineering are closely related fields. In fact, tissue engineering can be viewed as a special case of drug delivery where the goal is to accomplish controlled delivery of mammalian cells. Controlled release of therapeutic factors in turn will enhance the efficacy of tissue engineering. From a materials point of view, both the drug-delivery vehicles and tissue-engineering scaffolds need to be biocompatible and biodegradable. The biological functions of encapsulated drugs and cells can be dramatically enhanced by designing biomaterials with controlled organizations at the nanometer scale. This review summarizes the most recent development in utilizing nanostructured materials for applications in drug delivery and tissue engineering.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanostructured materials for applications in drug delivery and tissue engineering

Goldberg

Langer

Jia

2007

Journal of Biomaterials Science, Polymer Edition

943

554

View full text Add to dashboard Cite

show abstract

“…Only half of that number of boron atoms (3.8 Â 10 5 ) can be encapsulated in 100 nm liposomes at a dodecaborate cluster concentration of 0.1 M (assuming a volume per liposome of 5.2 Â 10 6 nm 3 ). The liposomes prepared here can most probably be tagged with tumor-seeking entities [19] and thereby a selective tumor accumulation should be possible.…”

Section: Resultsmentioning

confidence: 99%

Dodecaborate cluster lipids with variable headgroups for boron neutron capture therapy: Synthesis, physical–chemical properties and toxicity

Schaffran

Lissel

Samatanga

et al. 2009

Journal of Organometallic Chemistry

View full text Add to dashboard Cite

“…In effect, targeted liposomes reach tumors by the same passive targeting mechanism as nontargeted liposomes, i.e., by extravasating through gaps in tumor capillary endothelium. Hence, the number of targeted liposomes that reach the tumor interstitial space is no higher than the number of non-targeted liposomes [23,28,33,48,68,69]. Further, the binding of LTLs to the first tumor cells they encounter, retards their diffusion through the tumor parenchyma, a phenomenon referred to as the 'binding site barrier' [70].…”

Section: E Selection Of Target Tissues or Cellsmentioning

confidence: 99%

Ligand-Targeted Liposomes for Cancer Treatment

Sapra

Tyagi²,

Allen

2005

CDD

228

138

View full text Add to dashboard Cite

Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors expressed on cancer cells is a recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics or gene therapeutics. Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection criteria for the receptors to be targeted, choice of targeting ligands and choice of encapsulated therapeutics. Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. Ligand-targeted liposomes have shown considerable promise in preclinical xenograft models and are poised for clinical development.

show abstract

Untitled

Abstract: TF-PEG-liposomes had the capabilities of specific receptor binding and receptor-mediated endocytosis to target cells after extravasation into solid tumors in vivo. Such liposomes should be useful for in vivo cytoplasmic targeting of chemotherapeutic agents or plasmid DNAs to target cells.

Cited by 246 publications

References 21 publications

Nanostructured materials for applications in drug delivery and tissue engineering

Nanostructured materials for applications in drug delivery and tissue engineering

Dodecaborate cluster lipids with variable headgroups for boron neutron capture therapy: Synthesis, physical–chemical properties and toxicity

Ligand-Targeted Liposomes for Cancer Treatment

Contact Info

Product

Resources

About